Article Text

Download PDFPDF

470 MNRR1 inhibition, a potential therapeutic avenue for breast cancer
  1. Fiona Samson1,
  2. Neeraja Purandare2 and
  3. Siddhesh Aras2
  1. 1Troy, MI, USA
  2. 2Wayne State University, Detroit, MI, USA
  • Journal for ImmunoTherapy of Cancer (JITC) preprint. The copyright holder for this preprint are the authors/funders, who have granted JITC permission to display the preprint. All rights reserved. No reuse allowed without permission.


Background According to the American Cancer society there is a 1 in 8 chance that a woman in the United States will develop breast cancer. Additionally, 43,700 women are predicted to die from breast cancer in 2023.1 Current breast cancer treatments, including anti-cancer drugs such as daunorubicin, cause harmful side effects such as hair loss, difficulty breathing, severe decrease in red blood cell count in bone marrow, and life-threatening heart problems. Therefore, there is an urgent need for identifying novel targets for intervention with reduced toxicity. In breast cancer cells the protein Mitochondria Nuclear Retrograde Regulator 1 (MNRR1) is highly expressed compared to healthy cells. MNRR1 is a biorganellar protein that controls cellular function by acting in two compartments. In the mitochondria, it enhances energy production and inhibits apoptosis,2 3 whereas in the nucleus, it controls the transcription of genes involved in stress-responsive pathways.4 Since MNRR1 controls two key features of cancers- energy production which may affect cellular growth; and apoptosis, we hypothesized that MNRR1 may play a role in carcinogenesis and that inhibition of MNRR1 could reduce the dose of anti-cancer drugs such as daunorubicin and thereby minimize the toxic side effects of anti-cancer drugs.

Methods We treated triple negative breast cancer cells (MDA-MB-231)5 with an MNRR1 inhibitor and analyzed the effects on cellular apoptosis using a Phosphatidylserine Apoptosis Assay. We then assessed the viability of cells that were treated with both daunorubicin and the MNRR1 inhibitor using a RealTime-Glo MT Cell Viability Assay. Further, we evaluated the changes in expression levels of MNRR1 and PARP in the cells after treatment with the drugs via Western blotting.

Results Our results indicated that treatment of breast cancer cells with MNRR1 inhibitor alone reduced cell count (figure 1) even though it did not significantly increase apoptosis (figure 2). However, when co-treated with daunorubicin it increased the expression of cleaved PARP (figure 3), an indicator of apoptosis, and increased cell death (figure 4). These results suggest that MNRR1 inhibitor has a potentiating effect in inducing apoptosis in triple-negative breast cancer cells treated with daunorubicin.

Conclusions Overall, these findings suggest that MNRR1 is a potential drug target, and its inhibition may improve cancer treatment paradigms, such as the use of daunorubicin, by reducing the dose and therefore toxicity of drugs that are currently used in the treatment of breast cancer.

Acknowledgements We would like to thank the BCAP program at Wayne State University for supporting this study.


  1. Ullah FM. Breast Cancer: Current Perspectives on the Disease Status. Adv Exp Med Biol. 2019; 1152: 51–64.

  2. Liu Y, Zhang Y. CHCHD2 connects mitochondrial metabolism to apoptosis. Molecular & Cellular Oncology. 2015; Issue 4: 2.

  3. Kee TR, Gonzalez PE, Wehinger JL, Bukhari MZ, Ermekbaeva A, Sista A, Kotsiviras P, Liu T, Kang DE, Woo JA. Mitochondrial CHCHD2: Disease-Associated Mutations, Physiological Functions, and Current Animal Models. Front Aging Neurosci. 2021; 13: 660843.

  4. Gundamaraju R, Lu W, Manikam R. CHCHD2: The Power House’s Potential Prognostic Factor for Cancer? Frontiers in Cell and Developmental Biology. 2020; 8: 620816.

  5. Aras S, Maroun MC, Song Y, Bandyopadhyay S, Stark A, Yang ZQ, Long MP, Grossman LI, Fernández-Madrid F. Mitochondrial autoimmunity and MNRR1 in breast carcinogenesis. BMC Cancer. 2019; 19(1): 411.

Abstract 470 Figure 1

MNRR1 inhibition reduces cell count. In the vehicle treated sample, the cells are larger, more clumped together, and have a higher cell count, 24 hours post treatment. In the MNRR1 inhibited sample, the cells are smaller, spread farther apart, and have a lesser cell count. This suggests that inhibition of MNRR1 decreases the proliferation of breast cancer cells. The images are representative of 3 biological replicates, scale bar = 200μm

Abstract 470 Figure 2

MNRR1 inhibition does not induce apoptosis. Bar graph shows that over a period of 24 hours, cells treated with the MNRR1 inhibitor had increased amounts of apoptosis compared to the control cells, but not large enough to be significant. The results are expressed as mean ± standard deviation, n = 3–6

Abstract 470 Figure 3

MNRR1 inhibition induces apoptosis when co-treted with dunorubicin. Western blot shows that co-treatment with MNRR1 inhibitor significantly increased the cleaved PARP levels when compared to treatment with daunorubicin alone. Tubulin was used to normalize the protein expression levels. The images are representative of 3 biological replicates

Abstract 470 Figure 4

MNRR1 inhibition enhances daunorubicin-mediated cell death. The RealTime-Glo MT Cell Viability Assay indicated that the amount of breast cancer cell de ath is significantly increased after co-treatment with MNNR1 inhibitor compared to treatment with daunorubicin alone. The results are expressed as mean ± standard deviation, n = 7, *** indicates p<0.001

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.